Brief: Summit Therapeutics Withdraws Proposed Underwritten Public Offering Effective- SEC Filing
11/06/2026 13:02
BRIEF-Summit Therapeutics Withdraws Proposed Underwritten Public Offering Effective- SEC Filing June 11 (Reuters) - Summit Therapeutics Inc SMMT.O:
SUMMIT THERAPEUTICS - WITHDRAWS PROPOSED UNDERWRITTEN PUBLIC OFFERING EFFECTIVE JUNE 10, 2026 - SEC FILING
SUMMIT THERAPEUTICS - NO SECURITIES TO BE SOLD IN PROPOSED UNDERWRITTEN PUBLIC OFFERING - SEC FILING
Source text: [ID:n0001599298-26-000052]
Further company coverage: SMMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Summit Therapeutics
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
Brief: Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma
Factbox: Major drugmakers turn to China for licensing deals
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (updated)